In September 2025, the FDA approved new treatments for breast, bladder and prostate cancers, plus biosimilars and a subcutaneous immunotherapy option. The FDA approved the denosumab biosimilars Enoby ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback